Mature ovarian teratoma

Summary

Mature ovarian teratoma (MONDO:0003820) is a disease and 1 clinical trial. A subtype of mature teratoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	mature ovarian teratoma
Mondo ID	MONDO:0003820
DOID	DOID:6231
NCIT	C8112
UMLS	C1334637
MedGen	233672
GARD	0023683
Anatomy (UBERON)	UBERON:0000992
Is cancer (heuristic)	no

Also known as: mature ovarian teratoma · mature teratoma · mature teratoma of ovary · ovary mature teratoma

Disease family

This is a subtype of mature teratoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › germ cell tumor › nongerminomatous germ cell tumor › teratoma › mature teratoma › mature ovarian teratoma

Related subtypes (3): central nervous system mature teratoma, mature pericardial teratoma, mature gastric teratoma

Subtypes (3): childhood mature teratoma of the ovary, ovarian fetiform teratoma, ovarian solid teratoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06915103	Not specified	COMPLETED	A Case Report of NMDAR Encephalopathy